Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-10-02

Clinical Trial Update: Efficacy and Tolerance of Flucortac in Patients With Orthostatic Neurogenic Hypotension [Phase 4]

View source ↗

Summary

Phase 4 trial update reporting efficacy and tolerance of Flucortac in patients with neurogenic orthostatic hypotension.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Flucortac

Snippet

Sponsor: H.A.C. PHARMA | Conditions: Neurogenic Orthostatic Hypotension | Phase 4 | Status: UNKNOWN